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Sexual Dysfunction
Impact of Lower Urinary Tract Symptoms/Benign Prostatic 
Hyperplasia Treatment with Tamsulosin and Solifenacin 
Combination Therapy on Erectile Function
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Purpose: To examine the effects on erectile function of concomitant treatment with an 
alpha-blocker (tamsulosin) and an antimuscarinic agent (solifenacin) in patients with 
lower urinary tract symptoms (LUTS)/benign prostatic hyperplasia (BPH).
Materials and Methods: Fifty-seven male patients with LUTS/BPH were assessed for 
the degree of LUTS and erectile function. In group 1 (tamsulosin) and group 2 (tamsulosin 
and solifenacin), changes in the International Prostate Symptom Score [IPSS: total scores, 
storage symptoms (ST), voiding symptoms (VD), and quality of life (QoL)], prostate-spe-
cific antigen, trans-rectal ultrasonography, urine flowmetry, residual urine, and a 
5-item version of the International Index of Erectile Function (IIEF-5) were assessed 
after a 3-month treatment period. In both groups, it was determined whether treatment 
was associated with changes in LUTS and erectile function and whether improvement 
in the IPSS was correlated with the IIEF-5. Comparative analysis was also done to ex-
amine the linear relationship between improved IPSS scores and IIEF-5 scores.
Results: A comparison of the degree of improvement in all the parameters indicated 
that both groups showed significant improvement in total IPSS, IPSS-ST, IPSS-VD, 
and IPSS-QoL (p＜0.05). A comparison of the degree of improved sexual function associ-
ated with improved LUTS in each patient showed significant improvement in the IIEF-5 
score associated with the degree of improvement in the IPSS-ST domain in group 1, 
but no significant associations were found in group 2. In cases in which tamsulosin was 
administered, the IIEF-5 score significantly improved as the IPSS-ST domain score 
improved. In the group in which tamsulosin and solifenacin were concomitantly admini-
stered, improvement of the IPSS-ST domain score had no significant effect on the IIEF-5 
score.
Conclusions: In patients with LUTS/BPH, tamsulosin and solifenacin combination 
therapy was effective for LUTS, but erectile function was not significantly improved. 
Therefore, although effective for improving LUTS, combination therapy with an alpha- 
blocker and an antimuscarinic agent was not effective for improving erectile function. 
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INTRODUCTION
From a worldwide perspective, the life span of humans has 
been prolonged, and the proportion of elderly people in the 
total population has increased. Various changes occur in 
the human body with age. In elderly men, lower urinary 
tract symptoms (LUTS), erectile dysfunction (ED), and de-
creased libido often appear concurrently. Several commun-Korean J Urol 2011;52:49-54
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ity-based studies have shown a strong correlation among 
sexual dysfunction, increasing age, and the severity of 
LUTS. This coexistence of sexual problems with LUTS and 
benign prostatic hyperplasia (BPH) further affects quality 
of life (QoL) [1]. LUTS and ED share increased prevalence 
as age increases, and in many cases, the two are synchro-
nously present. Thus, continuous efforts have been made 
to disclose the common pathophysiology between these two 
conditions.
　No definite explanations have been given to clarify the 
pathophysiological mechanism of the correlation between 
LUTS and ED, but several hypotheses have been proposed 
[2-5]. One possible cause is overactivation of the autonomic 
nervous system and increased tension of the sympathetic 
nervous system. According to this hypothesis, LUTS in-
creases sympathetic nervous system activity, which in-
duces the occurrence of urinary storage symptoms due to 
the contraction of smooth muscles in the prostate gland and 
urinary bladder. ED occurs as the result of smooth muscle 
contractions in the corpus spongiosum, and the myosin 
light chain is phosphorylated because of increased 
Rho-kinase activity, which can cause smooth muscle layer 
contraction. It has been proposed that endothelial dysfunc-
tion in the prostate gland and corpus spongiosum and hor-
monal imbalance are physiological causes for the correla-
tion between LUTS and erectile dysfunction. Psychosocial 
factors have been proposed in addition to physiological 
causes. Changes in lifestyle due to nocturia and rapid eye 
movement sleep disorder may affect the occurrence of erec-
tile dysfunction. Also, the result of our preliminary study 
showed that age, International Prostate Symptom Score 
(IPSS), nocturia, and the uroflow rate correlated signi-
ficantly with the 5-item version of the International Index 
of Erectile Function (IIEF-5) [6]. Even in cases in which age 
was controlled for, QoL was found to have a significant cor-
relation with sexual function. Prostate gland volume was 
not significantly correlated with sexual function, implying 
that erectile function is not affected by subjective LUTS 
even with a relatively greater prostate size. Irwin et al re-
ported that overactive bladder (OAB) was significantly as-
sociated with increased prevalence of ED and that sexual 
activity, sexual enjoyment, and sexual satisfaction were 
reduced as the result of urinary symptoms [7]. 
　In recent years, many studies have reported that admin-
istration of alpha-blockers improves LUTS due to BPH and 
sexual dysfunction [8,9]. These findings suggest that rudi-
mentary treatments of LUTS, a risk factor for erectile dys-
function, would be mandatory to effectively improve sexual 
function in patients with BPH who concurrently have 
LUTS and ED. The primary treatment regimen for BPH 
is to administer alpha-blockers, for which the main mode 
of action is based on smooth muscle relaxation in the pro-
state and the resulting improvement in the urinary flow 
rate and voiding symptoms. However, a synchronous im-
provement of irritative and voiding symptoms may be the 
most effective treatment regimen for LUTS/BPH. It is ex-
pected that the concomitant administration of alpha- 
blockers and anticholinergics would improve LUTS more 
effectively in patients with LUTS/BPH. These effects are 
also expected to have a positive effect in secondarily im-
proving sexual function. Thus, the aim of this study was to 
examine the effects on erectile function of a combination 
of the alpha-blocker tamsulosin to improve LUTS and the 
antimuscarinic agent solifenacin to improve irritative 
symptoms of the bladder.
MATERIALS AND METHODS
Male patients aged 40 years or older who had concurrent 
LUTS/BPH and ED were enrolled in this study. Inclusion 
criteria were an IPSS total score ＞12, an IPSS-QoL score 
＞3, and an IIEF-5 score ＜20. Exclusion criteria were as 
follows: 1) antiandrogens administered in the 4 weeks pre-
viously for the management of BPH or LUTS; 2) sex hor-
mone agents or PDE-5 inhibitors administered in the 4 
weeks previously for the management of male sexual dys-
function; 3) surgical treatment of the prostate gland or ure-
thra; 4) diagnosis of urethral stricture, urinary tract in-
fection, prostatitis, prostate cancer, or bladder cancer; 5) 
PSA ＞4 mg/dl; 6) severe renal dysfunction or hepatic dys-
function; 7) residual urine ＞100 ml; and 8) ineligibility for 
the current study as judged by the investigators.
　Sixty male patients between the ages of 41 and 76 years 
with LUTS/BPH and ED were divided into two groups by 
using a table of random sampling numbers: group 1 (the 
alpha-blocker treatment group; n=30) and group 2 (the al-
pha-blocker＋solifenacin treatment group; n=30). In group 
1, an alpha-blocker (tamsulosin 0.2 mg q.d.) was solely ad-
ministered for 3 months. In group 2, an alpha-blocker and 
an antimuscarinic drug (tamsulosin 0.2 mg and solifenacin 
5 mg q.d) were concomitantly administered during the 
same period. In patients who were suspected of having a 
significant bladder outlet obstruction (postvoiding re-
sidual urine ＞100 ml or maximum flow rate ＜5 ml/s), sol-
ifenacin was not administered.
　To examine the correlation between LUTS and the de-
gree of erectile function, IPSS and IIEF-5 were evaluated. 
Then, prostate-specific antigen (PSA), transrectal ultra-
sonography (TRUS), urine flowmetry (UFM), and residual 
urine (RU) were measured. IPSS was categorized into total 
scores, storage symptoms (ST), voiding symptoms (VD), 
and quality of life (QoL). In group 1, in which tamsulosin 
was solely administered (n=30) for 3 months, and group 2, 
in which tamsulosin and solifenacin were concomitantly 
administered (n=30) for 3 months, IPSS, IIEF-5, UFM, and 
RU were measured again. Comparative analyses were also 
done to examine the linear relationship between IPSS 
scores and IIEF-5 scores before and after treatment in the 
two groups.
1. Statistical analysis
The t-test (T) and Mann-Whitney U-test were used to com-
pare parameters indicating the degree of LUTS and sexual 
function between the two groups, such as TRUS, PSA, IPSS Korean J Urol 2011;52:49-54
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TABLE 1. Changes in LUTS and erectile function before and after treatment in groups 1 and 2
Group 1: Tamsulosin (n=29) Group 2: Tamsulosin＋Solifenacin (n=27)
Before 3 mo Δ
a p-value Before 3 mo Δ p-value
Age (yr) 59.17±6.73 56.41±0.80
Prostate size (g) 27.1±8.0 28.43±8.18
PSA (mg/dl) 1.09±0.97 1.18±0.80
IPSS-Total 20.28±7.39 14.55±7.49 5.724 ＜0.001
b 15.22±5.55 11.07±7.23 4.148 0.001
b
IPSS-VD 12.38±5.19 8.69±5.08 3.690 ＜0.001
b 9.15±4.37 7.11±5.48 2.037 0.033
b
IPSS-ST 8.10±3.51 5.86±3.44 2.241 ＜0.001
b 6.08±2.83 3.96±2.77 2.111 ＜0.001
b
IPSS-QoL 4.28±0.88   3.45±1.298 0.828 0.006
b 3.82±0.88        3±1.271 0.815 0.001
b
IIEF-5 total 12.45±6.85 12.10±5.996 0.345 0.704 12.04±7.65 10.41±6.687 1.630 0.145
Void V (ml) 245.86±160.97 253.35±146.74 7.483 0.957 223.36±125.76 242.68±137.48 19.320 0.716
PVR (ml)      24±34.50 20.86±27.26 3.138 0.467   32.2±39.79   30.6±38.14 1.600 0.981
Qmax (ml/sec) 14.41±7.16 15.51±5.91 1.100 0.324 14.80±6.1 14.65±6.38 0.152 0.903
Qave (ml/sec) 7.33±3.62 8.28±3.63 0.948 0.093 8.06±3.53 8.15±3.69 −0.088 0.896
LUTS: lower urinary tract symptoms, PSA: prostate-specific antigen, IPSS-Total: International Prostate Symptom Score total score,
IPSS-VD: IPSS voiding domain, IPSS-ST: IPSS storage domain, IPSS-QoL: IPSS quality of life, IIEF-5: International Index of Erectile
Function-5,  Void V: voiding volume, PVR: postvoiding residual urine, Qmax: maximal urine flow rate, Qave: average flow rate, 
a: differ-
ence before and after treatment in group 1 and 2, 
b: p＜0.05
TABLE 2. Changes in LUTS and erectile function following 
treatment in both groups
Tamsulosin 
(n=29)
Tamsulosin＋
Solifenacin 
(n=27)
tp - v a l u e
IPSS-Total 5.72±6.90 4.15±5.72  0.926  0.358 
IPSS-VD 3.69±4.77 2.04±4.71 1.304  0.198 
IPSS-ST 2.24±3.50 2.11±2.33  0.163  0.871 
IPSS-QoL 0.83±1.47 0.82±1.04 0.037  0.970 
IIEF-5 −0.35±4.84  −1.63±5.64 0.917  0.363 
LUTS: lower urinary tract symptoms, IPSS-Total: International
Prostate Symptom Score total score, IPSS-VD: IPSS voiding do-
main, IPSS-ST: IPSS storage domain, IPSS-QoL: IPSS quality of
life, IIEF-5: International Index of Erectile Function-5
(total, VD, and ST), IPSS-QoL, IIEF-5 total, amount of uri-
nation, amount of RU, maximal urinary flow rate (Qmax), 
and mean urinary flow rate (Qave). By use of the paired 
t-test (T) and Wilcoxon Signed Rank Test (Z), a comparative 
analysis was performed on each group for IPSS (VD, ST, 
total), IPSS-QoL, IIEF-5 total, the amount of urination, the 
amount of RU, Qmax, and Qave before and after treatment. 
Regression analysis was used to inspect the linear relation-
ship between IPSS scores and IIEF-5 scores before and af-
ter treatment in the two groups. Statistical significance 
was set at p＜0.05.
RESULTS
Of a total of 60 study patients, 1 patient in group 1 and 3 
patients in group 2 dropped out of the 3-month follow-up 
study. Therefore, analyses were performed on 29 patients 
in group 1 and 27 patients in group 2. The incidences of hy-
pertension and diabetes were 11 and 3 in group 1 and 9 and 
5 in group 2, respectively. Before treatment, no significant 
differences (p＜0.05) were found between groups 1 and 2, 
respectively, in age (59.17±6.73 yr vs. 56.41±0.80 yr), pros-
tate gland size (27.1±8.0 g vs. 28.43±8.18 g), PSA levels 
(1.09±0.97 mg/dl vs. 1.18±0.80 mg/dl), amount of urination 
(245.86±160.97 ml vs. 223.36±125.76 ml), amount of RU 
(24± 34.50 ml vs. 32.2±39.79 ml), Qmax (14.41±7.16 ml/s 
vs. 14.80±6.1 ml/s), or Qave (7.33±3.62 ml/s vs. 8.06±3.53 
ml/s). No significant differences were found in IIEF-5 
(12.45± 6.85 vs. 12.04±7.65) or IPSS-QoL (4.28±0.88 vs. 
3.82±0.88) scores. However, the IPSS total score was sig-
nificantly higher (p＜0.05) in group 1 than in group 2 
(20.28±7.39 vs. 15.22±5.55). This was due to the exclusion 
of patients in group 2 who were suspected of having sig-
nificant bladder outlet obstruction (postvoiding residual 
urine ＞100 ml or maximum flow rate ＜5 ml/s). 
　In both groups 1 and 2, the IPSS total, IPSS-VD, IPSS- 
ST, and IPSS-QoL scores were significantly improved after 
the 3-month treatment (p＜0.05). However, no significant 
differences in the IIEF-5 total score, amount of urination, 
amount of RU, Qmax, or Qave were found before or after 
treatment (Table 1). 
　A comparison of the change (Δ) in LUTS and sexual func-
tion after treatment between group 1 and group 2 revealed 
no significant differences in ΔIPSS total (5.72±6.90 vs. 4.15± 
5.72), ΔIPSS-VD (3.69±4.77 vs. 2.04 ±4.71), ΔIPSS-ST (2.24± 
3.50 vs. 2.11±2.33), ΔIPSS-QoL (0.83±1.47 vs. 0.82±1.04), 
or ΔIIEF-5 (−0.35±4.84 vs. −1.63±5.64) (Table 2).
　A comparison of the degree of improved sexual function 
(ΔIIEF-5) associated with improved LUTS in each patient 
(ΔIPSS total, ΔIPSS-VD,  ΔIPSS-ST, and ΔIPSS-QoL) 
showed significant improvement in the IIEF-5 score asso-
ciated with the degree of improvement in the IPSS-ST do-
main (ΔIPSS-ST) in group 1, but no significant associations 
were found in group 2 (Table 3, Fig. 1). In cases in which Korean J Urol 2011;52:49-54
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FIG. 1.  Changes in IIEF-5 scores (IIEF-5) associated with improved IPSS-ST domain (IPSS-ST) in groups 1 and 2. In group 1 
(tamsulosin solely administered), the storage (or irritative) symptom score (IPSS-ST) was significantly associated with erectile 
function (IIEF-5) depending on the degree of improvement (F=5.176, p=0.031; R
2=0.16) (A). In group 2 (tamsulosin and solifenacin 
concomitantly administered), storage symptoms (IPSS-ST) showed no significant association with erectile function (IIEF-5) in 
relation to the degree of improvement (B). IIEF-5: International Index of Erectile Function-5, IPSS-ST: IPSS storage domain.
TABLE 3. Effects of improvement in LUTS on erectile function
ΔIPSS Total ΔIPSS-VD ΔIPSS-ST ΔIPSS-QoL
ΔIIEF-5 (Group 1, n=29) Pearson r 0.228 0.039      0.401
a     0.022
p-value 0.234 0.843      0.031
a     0.912
ΔIIEF-5 (Group 2, n=27) Pearson r 0.187 0.272 −0.091 −0.019
p-value 0.351 0.170     0.651     0.923
LUTS: lower urinary tract symptoms, IPSS-Total: International Prostate Symptom Score total score, IPSS-VD: IPSS voiding domain,
IPSS-ST: IPSS storage domain, IPSS-QoL: IPSS quality of life, IIEF-5: International Index of Erectile Function-5, Δ: change rate 
(difference), r: coefficient of correlation, 
a: p＜0.05
tamsulosin was administered, the IIEF-5 score significantly 
improved as the IPSS-ST domain score improved. In the 
group in which tamsulosin and solifenacin were con-
comitantly administered, improvement of the IPSS-ST do-
main score had no significant effect on the IIEF-5 score. 
DISCUSSION
LUTS/BPH is the most common disease of lower urinary 
tract obstruction that occurs in men aged 60 years or older. 
In most cases, it develops slowly, but in some patients, it 
progresses rapidly. LUTS aggravated by BPH causes de-
creased quality of life and sexual dysfunction. The incidence 
of both BPH and ED is increased in elderly people, and the 
synchronous occurrence of LUTS and ED is considered to 
happen as the result of aging. Even in cases in which age 
and underlying disease such as cardiovascular disease, 
diabetes mellitus, and hypertension were statistically con-
trolled, epidemiologic studies have shown a definite corre-
lation between BPH and ED [10]. These two disease enti-
ties are not due to aging, but they share a common patho-
physiology. Thus, a synergistic effect whereby the treat-
ment of one disease would lead to improvement in the other 
disease is expected. Lowe reported that treatment of BPH 
led to improved sexual function [11]. Conversely, Köhler 
and McVary reported that the improved sexual function re-
sulting from treatment with PDE-5 inhibitors led to im-
proved LUTS [12]. A questionnaire study of 12,815 men 
aged 50 years or older found a significant correlation be-
tween BPH and ED. Furthermore, age and LUTS were 
found to be greater risk factors for ED than were organic 
factors such as diabetes mellitus, hypertension, and hyper-
lipidemia [13]. In our series, age had the highest degree of 
correlation with sexual function [6]. Voiding symptoms of 
the IPSS, storage symptoms, QoL, nocturia symptoms, re-
sidual urine, maximal urinary flow rate, and mean urinary 
flow rate were significantly correlated with the degree of 
sexual satisfaction as well as with erectile function. 
　LUTS accompanied by BPH can be divided mainly into 
voiding (obstructive) symptoms and storage (irritative) 
symptoms. It has been well established that LUTS/BPH is 
closely linked to ED. However, little is known about which 
of the various symptoms are more closely associated with 
ED. It remains unclear which LUTS might effectively im-
prove the concurrent presence of ED, and a substantial 
number of studies in recent years have aimed to resolve this 
issue. This study was also performed to investigate which 
symptoms of BPH, obstructive or irritative symptoms, are Korean J Urol 2011;52:49-54
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closely related to erectile function. Morant et al reported 
that both irritative and voiding symptoms are significantly 
correlated with sexual function [14]. Tsai et al reported 
that irritative symptoms are more highly correlated with 
ED than are obstructive symptoms [15]. A preliminary 
study that we conducted in patients with BPH found a sig-
nificant correlation between sexual function and various 
irritative and voiding symptoms, QoL, nocturia, residual 
urine, and urine flow rates. Following a 3-month treatment 
of LUTS with alpha-blockers, the improvement in voiding 
symptoms, QoL, and average flow rate was significantly 
correlated with improved sexual function [6]. To date, how-
ever, few studies have reported similar results, and con-
troversy remains. This matter should be explored further. 
　In 50% to 75% of patients with LUTS/BPH, OAB is also 
present [16]. Even after the treatment of BPH, approx-
imately 38% of total cases have been reported to have per-
sistent OAB [17]. Storage symptoms due to OAB may cause 
a higher degree of pain than do voiding symptoms [18]. In 
cases of BPH accompanied by OAB, a single use of alpha- 
blockers is insufficient for obtaining treatment effects. For 
this reason, the use of anticholinergic agents (or antimus-
carinic agents) has been attempted in patients with OAB 
accompanied by BPH. Several previous studies have con-
firmed the efficacy and safety of concomitant admin-
istration of alpha-blockers and anticholinergic agents [19]. 
Even so, in some cases, residual urine is increased or void-
ing symptoms are aggravated following the use of anti-
cholinergic agents, and in patients with LUTS/BPH, anti-
cholinergic agents are used selectively. In our series, we ex-
cluded patients who likely had a significant bladder outlet 
obstruction (PVR ＞100 ml or Qmax ＜5 ml/s) and who had 
LUTS/BPH; we therefore found significantly improved 
LUTS with no complications such as acute urinary retention. 
　Common side effects following the use of anticholinergic 
(or antimuscarinic) agents are dry mouth, constipation, 
blurred vision, headache, and dry eye, but almost no re-
ports have described the effects on sexual function. Some 
concern exists that the use of anticholinergic (or anti-
muscarinic) agents in patients with BPH may lead to ag-
gravation of voiding difficulty or the development of uri-
nary retention. To date, urologists have not actively used 
anticholinergic (or antimuscarinic) agents, but many types 
of antimuscarinic agents have been used in recent years to 
treat OAB in a clinical setting. As related experiences have 
accumulated, these drugs have been selectively used for 
patients with LUTS/BPH [20]. Almost no reports have ad-
dressed the effects of antimuscarinic agents on sexual func-
tion in LUTS/BPH patients. In a study of 39 men with BPH 
and LUTS in whom previous alpha-blocker therapy had 
failed, Kaplan et al found normal sexual function in 27 
(63%) and 29 (67%) patients before and after administration, 
respectively [21]. Furthermore, mean IIEF-EF domain 
scores improved by 6.9 points. No reports have indicated 
that the administration of anticholinergic (or antimuscari-
nic) agents significantly impairs sexual function. In our 
series, a comparison of IIEF-5 scores before and after con-
comitant drug treatment with solifenacin and tamsulosin 
revealed no statistically significant changes. Thus, it can 
be inferred that administration of anticholinergic (or anti-
muscarinic) agents had no significant effect on sexual 
function. In patients with LUTS/BPH, concomitant treat-
ment with alpha-blockers and antimuscarinics may lead 
to improvement in LUTS, but this treatment cannot be ex-
pected to improve sexual function. 
CONCLUSIONS
In patients with LUTS/BPH and ED, concomitant use of 
tamsulosin and solifenacin was effective for improving 
LUTS. However, sexual function was not significantly im-
proved by the concomitant administration of alpha-block-
ers and antimuscarinics. 
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